|
Synonyms: BIIB-067 | BIIB067 | Qalsody®
tofersen is an approved drug (FDA (2023), EMA (2024))
Compound class:
Nucleic acid
Comment: Tofersen (BIIB067) is an antisense oligonucleotide that disrupts translation of superoxide dismutase 1 (SOD1). Tofersen was designed to treat cases of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) that are associated with expression of mutated SOD1. In fact tofersen is mutation agnostic, and disrupts expression of normal and mutated, toxic forms of the SOD1 protein. SOD1-ALS/MND accounts for ~2% of all cases.
|
Classification ![]() |
|
| Compound class | Nucleic acid |
| Compound subclass | Antisense oligonucleotide (ASO) |
| Target | SOD1 mRNA |
| Approved drug? | Yes. China NMPA (2024) | EU EMA (2024) | US FDA (2023) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10804 | tofersen |
Synonyms ![]() |
| BIIB-067 | BIIB067 | Qalsody® |
Database Links ![]() |
|
| CAS Registry No. | 2088232-70-4 (source: WHO INN record) |
| ChEMBL Ligand | CHEMBL3833346 |
| DrugBank Ligand | DB14782 |
| GtoPdb PubChem SID | 500839946 |
| Search PubMed clinical trials | tofersen |
| Search PubMed titles | tofersen |
| Search PubMed titles/abstracts | tofersen |